Open AccessImpact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae
Author(s) -
Sarah M. Bartsch,
Susan S. Huang,
Kim F. Wong,
Rachel B. Slayton,
James A. McKinnell,
Daniel F. Sahm,
Krystyna M. Kazmierczak,
Leslie E. Mueller,
John A. Jernigan,
Bruce Y. Lee
Publication year - 2016
Publication title -
journal of clinical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.349
H-Index - 255
eISSN - 1070-633X
pISSN - 0095-1137
DOI - 10.1128/jcm.00635-16
Subject(s) - carbapenem resistant enterobacteriaceae , food and drug administration , carbapenem , enterobacteriaceae , clinical microbiology , medicine , intensive care medicine , microbiology and biotechnology , biology , environmental health , antibiotics , escherichia coli , biochemistry , gene
Delays often occur between CLSI and FDA revisions of antimicrobial interpretive criteria. Using our Regional Healthcare Ecosystem Analyst (RHEA) simulation model, we found that the 32-month delay in changing carbapenem-resistant Enterobacteriaceae (CRE) breakpoints might have resulted in 1,821 additional carriers in Orange County, CA, an outcome that could have been avoided by identifying CRE and initiating contact precautions. Policy makers should aim to minimize the delay in the adoption of new breakpoints for antimicrobials against emerging pathogens when containment of spread is paramount; delays of <1.5 years are ideal.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom